Global Malignant Melanoma Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 6.37 Billion |
 Market Size (Forecast Year) |
USD 14.12 Billion |
 CAGR |
% |
| Major Markets Players |
|
>全球恶性黑色素瘤治疗市场，按阶段（0 期、I 期、II 期、III 期、IV 期、复发性）、治疗（手术、放射治疗、化疗、靶向治疗、抑制剂）、药物（Opdivo、Yervoy、Mekinist+Tafinlar、Keytruda、Cotellic、Zelboraf、Imlygic、仿制药）划分 - 行业趋势和预测到 2030 年。
恶性黑色素瘤治疗市场分析及规模
全球人口中黑色素瘤和其他皮肤癌病例的增加以及增强癌症治疗的技术进步是推动恶性黑色素瘤治疗市场的主要因素。诸如在飞机上长时间工作、日光浴床使用和紫外线照射的增加以及臭氧水平下降等因素也通过增加癌症发病率影响恶性黑色素瘤治疗市场。对有效免疫疗法的需求增加、优质药品的渗透以及先进技术的采用率加速了恶性黑色素瘤治疗市场的发展。此外，政府为传播早期诊断和治疗意识而采取的举措以及推出疫苗和免疫疗法等新的靶向治疗方法对恶性黑色素瘤治疗市场产生了积极影响。此外，新型疗法的采用率上升以及食品和药物管理局的批准数量不断增加，为预测期内的恶性黑色素瘤治疗市场参与者提供了获利机会。
Data Bridge Market Research 分析，全球恶性黑色素瘤治疗市场规模在 2022 年为 63.7 亿美元，到 2030 年将飙升至 141.2 亿美元，预计 2023 年至 2030 年的复合年增长率为 11.8%。这表明了市场价值。由于皮肤癌数量不断增加，“0 期”在全球恶性黑色素瘤治疗市场的阶段部分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。
恶性黑色素瘤治疗市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史性的一年 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按阶段（0 期、I 期、II 期、III 期、IV 期、复发）、疗法（手术、放射疗法、化疗、靶向疗法、抑制剂）、药物（Opdivo、Yervoy、Mekinist+Tafinlar、Keytruda、Cotellic、Zelboraf、Imlygic、仿制药） |
|
覆盖国家 |
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America |
|
Market Players Covered |
Biogen (US), Bristol-Myers Squibb Company (US), Enzon Pharmaceuticals Inc. (US), GlaxoSmithKline plc (UK), Aptose Biosciences (Canada), Merck KGaA (Germany), ONO PHARMACEUTICAL CO. LTD.(Japan), DAIICHI SANKYO COMPANY LIMITED (Japan), Reliance Industries Limited (India), among other |
|
Market Opportunities |
|
Market Definition
Malignant melanoma refers to uncontrolled cell growth, which develops from melanocytes which are the pigment-producing cells in the body. Their cases have increased in the past few years worldwide, and they are rarely seen in the eyes, mouth, or intestine. They generally occur on the back of men and the legs of women. This cancer occur approximately 25% from moles.
Global Malignant Melanoma Treatment Market Dynamics
Drivers
- Notable Developments in terms of Market Players
Recently, there have been some promising and innovative developments in the global malignant melanoma market. The market has observed the presence of several noticeable market players, with each of the players competing for more revenue and greater reach. Relentless research and development activities have played a critical role in the expansion of the share of the market and growing revenue for the market players. This boosts market growth.
- Increasing Demand for Targeted Therapy
The rising demand for targeted therapy showed many advantages as it interferes with specific proteins involved in tumorigenesis, focusing on specific molecular changes, which stop the growth of various types of cancers. Several significant factors influenced melanoma growth, including the fewer adverse effects of the therapy and the availability of several targeted therapeutics. This boosts market growth.
Opportunities
Growing Healthcare Infrastructure and Policies
The presence of large patient pool, having a strong presence of key players, ease of drug availability, a well-established healthcare infrastructure, favourable reimbursement policies in the healthcare system, rise in R&D, and innovation activities and higher adoption of advanced therapeutics may create opportunities for the market.
Restraints/Challenges
Unavailability of Appropriate Treatments
To treat conditions that are rare, many a times all treatments are not available, especially in under-developed countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Thus, it hampers the market growth.
This global malignant melanoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the surgical microscopes market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In 2020, FDA approved the drug selumetinib of AstraZeneca and Merck & Co. to treat neurofibromatosis type 1, or NF1, a rare and characteristically inherited disease that causes tumors to grow inside nerve sheaths. In addition to this, Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.
Global Malignant Melanoma Treatment Market Scope
The global malignant melanoma treatment market is segmented on the basis of stage, therapy and drugs. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Stage
- STAGE 0
- STAGE I
- STAGE II
- STAGE III
- STAGE IV
- RECURRENT
Therapy
- SURGERY
- RADIATION THERAPY
- CHEMOTHERAPY
- TARGETED THERAPY
- INHIBITORS
Drugs
- OPDIVO
- YERVOY
- MEKINIST+TAFINLAR
- KEYTRUDA
- COTELLIC
- ZELBORAF
- IMLYGIC
- GENERIC DRUGS
Global Malignant Melanoma Treatment Market Regional Analysis/Insights
The global malignant melanoma treatment market is analyzed and market size insights and trends are provided by country, stage, therapy and drugs as referenced above.
The countries covered in the global malignant melanoma treatment market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
North America dominates the global malignant melanoma treatment market because of the increasing healthcare initiatives, the strong presence of major players in the market, increasing cases of melanoma and rising number of research activities in this region.
预计亚太地区将在 2023 年至 2030 年的预测期内实现显着增长，这得益于政府加强宣传力度、该地区研究活动不断增多、拥有大量未开发市场、人口众多以及对优质医疗服务的需求不断增长。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税的影响以及贸易路线。
医疗保健基础设施增长安装基础和新技术渗透
全球恶性黑色素瘤治疗市场还为您提供详细的市场分析，包括每个国家/地区资本设备医疗保健支出的增长、全球恶性黑色素瘤治疗市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管情景的变化及其对全球恶性黑色素瘤治疗市场的影响。数据适用于 2010-2020 年的历史时期。
竞争格局和全球两性霉素 B 市场份额分析
全球恶性黑色素瘤治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
全球恶性黑色素瘤治疗市场的一些主要参与者包括：
- Biogen（美国）
- 百时美施贵宝公司 (美国)
- Enzon Pharmaceuticals Inc.（美国）
- 葛兰素史克公司 (英国)
- Aptose Biosciences（加拿大）
- 默克集团（德国）
- 小野制药株式会社（日本）
- 第一三共株式会社（日本）
- 信实工业有限公司 (印度)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
